![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
|Articles|July 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 7
- Volume 17
- Issue 7
RAS Mutations Enhance Chemotherapy in AML
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission.
Advertisement
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.
Articles in this issue
about 18 years ago
National Cancer Survivors Dayabout 18 years ago
New Indication for Velcade in Previously Untreated Myelomaabout 18 years ago
Risk Factors for Mantle Cell Lymphoma Identifiedabout 18 years ago
Antidiabetic Agent Metformin May Boost pCRs in Breast Caabout 18 years ago
Eisai Seeks Full FDA Approval for Ontak for CTCLabout 18 years ago
Symptom Screen Plus CA125 Detects Early Ovarian Caabout 18 years ago
Cisplatin Linked to Cardiac Complications in Testicular Ca Patientsabout 18 years ago
Updated X-ACT Study Results Presentedabout 18 years ago
ThromboGenics and BioInvent Announce Alliance with Rocheabout 18 years ago
Gene Signature Identifies Low-Risk Patients in MAGE-A3 TrialAdvertisement
Related to this article
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5